Enteric Coated Mycophenolate Sodium

Pipeline

Status by Indication[2][1]

Competition

Competitive Landscape

5 competitors in Renal Allograft Recipients

#DrugCompanyPhaseTrials

1

Prograf

VVeloxis Pharmaceuticals

Approved

52

Cellcept

Roche

Phase 3

23

Nulojix

Bristol-Myers Squibb

Phase 3

14

Myfortic

Novartis

Phase 3

15

Cyclosporine a

Novartis

Phase 3

16

Enteric Coated Mycophenolate Sodium

Bristol-Myers Squibb

Phase 3

1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Renal Allograft Recipients1 trial

A Prospective, Open-label, Multicenter, Randomized Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Renal Allograft Recipients Aged 12 to Less Than 18 Years of Age to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications

Recruiting·Bristol-Myers Squibb·Phase 3·NCT04877288·102 enrolled

Details

Drug Info

Related News